Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

91 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis.
Navarese EP, Kolodziejczak M, Schulze V, Gurbel PA, Tantry U, Lin Y, Brockmeyer M, Kandzari DE, Kubica JM, D'Agostino RB Sr, Kubica J, Volpe M, Agewall S, Kereiakes DJ, Kelm M. Navarese EP, et al. Among authors: kolodziejczak m. Ann Intern Med. 2015 Jul 7;163(1):40-51. doi: 10.7326/M14-2957. Ann Intern Med. 2015. PMID: 25915661 Free article. Review.
Implantable Cardioverter-Defibrillators for Primary Prevention in Patients With Ischemic or Nonischemic Cardiomyopathy: A Systematic Review and Meta-analysis.
Kolodziejczak M, Andreotti F, Kowalewski M, Buffon A, Ciccone MM, Parati G, Scicchitano P, Uminska JM, De Servi S, Bliden KP, Kubica J, Bortone A, Crea F, Gurbel P, Navarese EP. Kolodziejczak M, et al. Ann Intern Med. 2017 Jul 18;167(2):103-111. doi: 10.7326/M17-0120. Epub 2017 Jun 27. Ann Intern Med. 2017. PMID: 28632280 Review.
Role of proprotein convertase subtilisin/kexin type 9 inhibitors in patients with coronary artery disease undergoing percutaneous coronary intervention.
Navarese EP, Kołodziejczak M, Petrescu A, Wernly B, Lichtenauer M, Lauten A, Buffon A, Wanha W, Pestrichella V, Sardella G, Contegiacomo G, Tantry U, Bliden K, Kubica J, Gurbel PA. Navarese EP, et al. Among authors: kolodziejczak m. Expert Rev Cardiovasc Ther. 2018 Jun;16(6):419-429. doi: 10.1080/14779072.2018.1474099. Epub 2018 May 23. Expert Rev Cardiovasc Ther. 2018. PMID: 29737886 Review.
Baseline low-density lipoprotein cholesterol to predict the extent of cardiovascular benefit from lipid-lowering therapies: a review.
Navarese EP, Andreotti F, Raggi P, Kolodziejczak M, Buffon A, Bliden K, Tantry U, Kubica J, Sardella G, Lauten A, Agewall S, Gurbel PA, Brouwer MA. Navarese EP, et al. Among authors: kolodziejczak m. Eur Heart J Cardiovasc Pharmacother. 2019 Jan 1;5(1):47-54. doi: 10.1093/ehjcvp/pvy038. Eur Heart J Cardiovasc Pharmacother. 2019. PMID: 30247574 Review.
Comprehensive meta-analysis of safety and efficacy of bivalirudin versus heparin with or without routine glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndrome.
Navarese EP, Schulze V, Andreotti F, Kowalewski M, Kołodziejczak M, Kandzari DE, Rassaf T, Gorny B, Brockmeyer M, Meyer C, Berti S, Kubica J, Kelm M, Valgimigli M. Navarese EP, et al. Among authors: kolodziejczak m. JACC Cardiovasc Interv. 2015 Jan;8(1 Pt B):201-213. doi: 10.1016/j.jcin.2014.10.003. Epub 2014 Nov 1. JACC Cardiovasc Interv. 2015. PMID: 25616926 Free article.
Comparative efficacy and safety of anticoagulant strategies for acute coronary syndromes. Comprehensive network meta-analysis of 42 randomised trials involving 117,353 patients.
Navarese EP, Andreotti F, Kołodziejczak M, Schulze V, Wolff G, Dias S, Claessen B, Brouwer M, Tarantini G, Iliceto S, Brockmeyer M, Kowalewski M, Lin Y, Eikelboom J, Musumeci G, Lee L, Lip GY, Valgimigli M, Berti S, Kelm M. Navarese EP, et al. Among authors: kolodziejczak m. Thromb Haemost. 2015 Nov;114(5):933-44. doi: 10.1160/TH14-12-1066. Epub 2015 Jul 16. Thromb Haemost. 2015. PMID: 26177601
91 results